secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K/A
Filed at:   2023-02-17T23:59:59+00:00
Accession:  0001493152-23-005438
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte corrects 2022 shareholder vote: equity plan amendment did not pass
---------------------------------------------------------------------------

- Amendment to 2018 Equity Incentive Plan to eliminate fungible share counting failed to receive majority of shares represented at meeting.
- Vote tally: 42,563,690 for, 30,005,136 against, 218,250 abstained, 21,793,461 broker non-votes.
- Required standard was majority of shares present; only 42.6M of ~74.6M shares represented voted in favor.
- Original 8-K erroneously stated proposal passed; this amendment corrects that error.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223005438/0001493152-23-005438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223005438/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-005438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer